FGF9 and non-small cell lung carcinoma: Among them, miR-219a-5p has been reported to play a crucial role in the development of acquired DDP resistance in NSCLC cells by targeting FGF9 and may serve as a therapeutic target for DDP resistance in clinical practice [14].